drugset / Trial / NCT02498379
PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis (Volunteer - BioD and Safety Study)
NaSingle-groupOpen-labelDiagnostic
Summary
This study is designed to assess the safety, biodistribution and dosimetry of the novel atherosclerotic imaging PET radiotracer, Cu\[64\]-25%-CANF-Comb.
Timeline
- Start
- 2014-10
- Primary completion
- 2015-04
- Completion
- 2015-04
Publications
- Background Liu Y, Pressly ED, Abendschein DR, Hawker CJ, Woodard GE, Woodard PK, Welch MJ. Targeting angiogenesis using a C-type atrial natriuretic factor-conjugated nanoprobe and PET. J Nucl Med. 2011 Dec;52(12):1956-63. doi: 10.2967/jnumed.111.089581. Epub 2011 Nov 2.
- Background Liu Y, Abendschein D, Woodard GE, Rossin R, McCommis K, Zheng J, Welch MJ, Woodard PK. Molecular imaging of atherosclerotic plaque with (64)Cu-labeled natriuretic peptide and PET. J Nucl Med. 2010 Jan;51(1):85-91. doi: 10.2967/jnumed.109.066977. Epub 2009 Dec 15.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cu[64]-25%CANF-Comb | Diagnostic / imaging agent | 148 mbq | Intravenous |
| Subject | Cu[64]-25%CANF-Comb | Diagnostic / imaging agent | 296 mbq | Intravenous |